ABL Diagnostics, a Euronext-listed company specialising in molecular biology assays and software for microbiology laboratories, has today released new DeepChek® assays for Influenza A, Influenza B, Respiratory Syncytial Virus (RSV) A and Respiratory Syncytial Virus B genotyping.
This comes as healthcare systems across the northern hemisphere prepare for the “tripledemic” of flu, SARS-CoV-2, and RSV infections. Respiratory syncytial virus (RSV) is a respiratory-borne infectious disease that leads to the inflammation of the smallest lung airways and is estimated to result in more than 3 million hospitalisations and more than 26,000 deaths per year globally.
The assays, available in a kit format, complete ABL Diagnostics’ portfolio of applications dedicated to the analysis of respiratory viruses and have been verified on several sequencing platforms.
Dr. Sofiane Mohamed, Head of R&D at ABL Diagnostics, said: “Our team keeps developing new applications on a regular basis with the objective of releasing end products matching as many settings as possible. As such, we have verified those new assays on several sequencing platforms and made sure RSV and Influenza samples can be multiplexed with other types of specimens within a single NGS run, to ensure maximal efficiency.”
Dimitri Gonzalez, Head of Diagnostics at ABL Diagnostics, added: “Innovation is part of the ABL Diagnostics DNA, we aim to consolidate our portfolio of applications and release new kits in line with our partners and customers’ expectations. Since the COVID-19 pandemic, we have learned the need to keep studying and tracking respiratory viruses and gathering knowledge and epidemiology information.”
The respiratory syncytial virus (RSV) diagnostic market is expected to register a significant CAGR of 10.1% during 2023 – 2028, driven by the growing burden of RSV infections globally, rise in investments, technological advancements in the development of RSV diagnostic tests, product approvals and launches, and other key strategies adopted by the market players.
ABL Diagnostics, based in Woippy, France, is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6).
Today, ABL Diagnostics has released new DeepChek® assays for Influenza A, Influenza B, Respiratory Syncytial Virus (RSV) A and Respiratory Syncytial Virus B genotyping. These assays complete the company’s portfolio of applications dedicated to the analysis of respiratory viruses and have been verified on several sequencing platforms.
As healthcare systems across the northern hemisphere prepare for the “tripledemic” of flu, SARS-CoV-2, and RSV infections, the respiratory syncytial virus (RSV) diagnostic market is expected to register a significant CAGR of 10.1% during 2023 – 2028.
Dr. Sofiane Mohamed, Head of R&D at ABL Diagnostics, said: “Our team keeps developing new applications on a regular basis with the objective of releasing end products matching as many settings as possible. As such, we have verified those new assays on several sequencing platforms and made sure RSV and Influenza samples can be multiplexed with other types of specimens within a single NGS run, to ensure maximal efficiency.”
Dimitri Gonzalez, Head of Diagnostics at ABL Diagnostics, added: “Innovation is part of the ABL Diagnostics DNA, we aim to consolidate our portfolio of applications and release new kits in line with our partners and customers’ expectations. Since the COVID-19 pandemic, we have learned the need to keep studying and tracking respiratory viruses and gathering knowledge and epidemiology information.”
ABL Diagnostics, based in Woippy, France, is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6).
Today, ABL Diagnostics has announced the release of new DeepChek® assays for Influenza A, Influenza B, Respiratory Syncytial Virus (RSV) A and Respiratory Syncytial Virus B genotyping. The assays, available in a kit format, complete the company’s portfolio of applications dedicated to the analysis of respiratory viruses, including SARS-CoV-2 Whole Genome sequencing and the simultaneous qualitative detection and differentiation of SARS
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.